Akebia Therapeutics, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Akebia Therapeutics, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Goodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative. Less tangible than 92% of Healthcare companies in United States.
- Debt Due Cover Ratio: Debt due within a year is covered 19.2 times by its yearly operating cash. Higher than 89% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 85% of its market value (net cash). Higher than 86% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
$15For every $100 of sales, $15 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $15 tied up three years earlier.
Less money tied up than 68% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 19%
Sales fell 19% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-19% / +6%In 3 years sales changed by -19% while total assets changed by +6%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
19.2×Debt due within a year is covered 19.2 times by its yearly operating cash.
Higher than 89% of Healthcare companies in United States.
Cash Cushion Ratio
+85%Cash, after subtracting all debt, equals 85% of its market value (net cash).
Higher than 86% of Healthcare companies in United States.
Tangible Assets Ratio
84%Of every $100 the company owns, $84 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 54% of Healthcare companies in United States.
Tangible Net Worth Ratio
NegativeGoodwill and other intangibles are larger than its whole net worth, so its tangible net worth is negative.
Less tangible than 92% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Akebia Therapeutics, Inc. made a loss over the last year. Akebia Therapeutics, Inc. owes $0.93 for every $1 it owns. Akebia Therapeutics, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAkebia Therapeutics, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
6.23The share price is 6.23 times Akebia Therapeutics, Inc.'s book value per share, higher than 77% of Healthcare companies in United States.
Market cap
$156 MThe total market value of all of Akebia Therapeutics, Inc.'s shares at today's price (share price × number of shares), smaller than 61% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$25 MWhat Akebia Therapeutics, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.09Net worth divided by the number of shares. The share price of $0.56 is 6.2 times this, which is the P/B above.
Return on equity (ROE)
-109.4%Akebia Therapeutics, Inc. lost 109.4% of its shareholders' money over the last year, lower than 73% of Healthcare companies in United States.
Owes vs Owns
0.93×Akebia Therapeutics, Inc. owes $0.93 for every $1 it owns (high), higher than 84% of Healthcare companies in United States.
Dividend yield
NoneAkebia Therapeutics, Inc. does not currently pay a dividend.
Revenue growth
+47%Revenue rose 47% in the year to Dec 2025, and shrank 7% a year on average over 3 years.
Profit growth
LossAkebia Therapeutics, Inc. made a loss in each of the last two years.
Profit margin
-2.3%Akebia Therapeutics, Inc. lost $2 for every $100 of revenue.
Interest cover
1.0×Akebia Therapeutics, Inc.'s operating profit covered its interest costs 1.0 times in the year to Dec 2025.
Cash vs debt
Net cashAkebia Therapeutics, Inc. held $133 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Akebia Therapeutics, Inc.: $156 M ÷ $25 M (30 Jun 2026) = 6.2.
What is Akebia Therapeutics, Inc.'s return on equity?
Akebia Therapeutics, Inc. lost 109.4% of its shareholders' money over the last year, lower than 73% of Healthcare companies in United States.
How much does Akebia Therapeutics, Inc. owe compared with what it owns?
Akebia Therapeutics, Inc. owes $0.93 for every $1 it owns (high), higher than 84% of Healthcare companies in United States.
Does Akebia Therapeutics, Inc. pay a dividend?
No. Akebia Therapeutics, Inc. does not currently pay a dividend.
Is Akebia Therapeutics, Inc.'s revenue growing?
Revenue rose 47% in the year to Dec 2025, and shrank 7% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.